Updates in kidney cancer at ESMO 2022

Joaquim Bellmunt, MD, PhD, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, discusses updates from ESMO 2022 for renal cell carcinoma, including checkpoint inhibitors, adjuvant immunotherapy, and results from the COSMIC-313 trial (NCT03937219). This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.